To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

NCT07505030 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

UC - Ulcerative Colitis

Interventions

DRUG: LYNC-101
DRUG: LYNC-101 Placebo

Sponsor

LyncBio Therapeutics Co., Ltd.